Cover Image
市場調查報告書

鼠疫 : 開發平台分析

Plague - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 245959
出版日期 內容資訊 英文 87 Pages
訂單完成後即時交付
價格
Back to Top
鼠疫 : 開發平台分析 Plague - Pipeline Review, H1 2017
出版日期: 2017年02月28日 內容資訊: 英文 87 Pages
簡介

鼠疫是由於鼠疫這種細菌所引起的傳染病。這個細菌主要寄生在老鼠身上的跳蚤上。人類及其他動物接觸到老鼠及被跳蚤叮咬而感染。過去鼠疫曾經造成人類全體文明崩潰。現代由於生活水準的改善及抗生物質的進步,鼠疫終於成了一般疾病。鼠疫的一般症狀出現在腹股溝及腋下、頭部等腹股溝腺炎(淋巴結腫起、感到痛的所在)。鼠疫中罕見的嚴重情況,會侵襲肺部,並由人類互相傳染。

本報告提供全球各國治療鼠疫所用的開發中產品之開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗各階段產品一覽,主要企業簡介,主要藥物概要(產品概要,功能機制,研究開發(R&D)的發展情形),最新的產業趨勢等調查,並將結果概述為以下內容。

簡介

  • 分析範圍

鼠疫概要

治療藥的開發

  • 鼠疫開發中產品:概要
  • 鼠疫開發中產品:比較分析

各企業開發中的鼠疫治療藥

大學/研究機關研究中的鼠疫治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

鼠疫治療藥:開發中的產品一覽(各企業)

鼠疫治療藥:研究中的產品一覽(大學/研究機關別)

鼠疫開發治療藥的企業

  • Aradigm Corporation
  • Grifols, S.A.
  • iBio, Inc.
  • Mucosis B.V.
  • Syntiron LLC
  • Tetraphase Pharmaceuticals Inc.

鼠疫:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各行動機制
  • 各投藥法
  • 各分子類型
  • 各治療分類

藥物簡介

  • 炭疽菌·鼠疫菌疫苗
  • ARD-3100
  • 鹽酸hydrochloride
  • 鼠疫菌疫苗
  • 肺血小板疫苗
  • 鼠疫蛋白質酪胺酸磷酸酶 (YopH) 抑制劑
  • TP-271
  • 鼠疫菌疫苗

鼠疫治療藥:最新的藥物簡介

鼠疫治療藥:暫停開發的產品

鼠疫治療藥:開發中止的產品

鼠疫相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8993IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Plague - Pipeline Review, H1 2017, provides an overview of the Plague (Infectious Disease) pipeline landscape.

Plague is an infection caused by the bacterium Yersinia pestis. The organism is transmitted to humans who are bitten by fleas that have fed on infected rodents or by humans handling infected animals. Symptoms include headache, fatigue or malaise, muscle aches, fever and chills, abdominal pain, diarrhea and vomiting, shock and bleeding from mouth, nose or rectum, or under skin. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Plague - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Plague (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Plague (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Plague and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical, Discovery and Unknown stages are 1, 14, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 3 and 1 molecules, respectively.

Plague (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Plague (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Plague (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Plague (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Plague (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Plague (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Plague (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Plague (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Plague - Overview
  • Plague - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Plague - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Plague - Companies Involved in Therapeutics Development
    • Achaogen Inc
    • Aradigm Corp
    • AvidBiotics Corp
    • Endacea Inc
    • GlaxoSmithKline Plc
    • Grifols SA
    • iBio Inc
    • Mucosis BV
    • Paratek Pharmaceuticals Inc
    • Prokarium Ltd
    • Syntiron LLC
    • Takeda Pharmaceutical Company Ltd
    • Tetraphase Pharmaceuticals Inc
  • Plague - Drug Profiles
    • (plague + small pox) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • anthrax + plague vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARD-3100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARD-3150 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BDM-I - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ciprofloxacin hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • gepotidacin mesylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GrePla - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ISAS-02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • L-971 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • omadacycline tosylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plague vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plague vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plague vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plague vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plague vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plague vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plague vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plague vaccine 2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plazomicin sulfate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pneumonic plaque vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein for Pneumonic Plague - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Yoph Protein Tyrosine Phosphatase for Plague - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TP-271 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Yersinia pestis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Plague - Dormant Projects
  • Plague - Discontinued Products
  • Plague - Product Development Milestones
    • Featured News & Press Releases
      • Oct 18, 2016: Aradigm Announces Multi-million Dollar DTRA Funding for Inhaled Ciprofloxacins Formulations
      • Feb 14, 2013: BioDiem Extends Cooperative Agreement With USAMRIID
      • Nov 19, 2012: UK Scientists Report On Efficacy Of Aradigm's Lipoquin Against Pneumonic Plague
      • Jun 05, 2008: Computer Sciences Corporation's DynPort Vaccine Company To Continue Plague Vaccine Development
      • Nov 18, 2005: Computer Sciences Corporation's DynPort Vaccine Company Reaches Milestone In Plague Vaccine Clinical Trial
      • May 17, 2005: Wake Forest Scientists Find New Combination Vaccine Effective Against Plague
      • Jan 10, 2005: Computer Sciences Corporation's DynPort Vaccine Company Enters Clinical Trial For Plague Vaccine Candidate
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Plague, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Plague - Pipeline by Achaogen Inc, H1 2017
  • Plague - Pipeline by Aradigm Corp, H1 2017
  • Plague - Pipeline by AvidBiotics Corp, H1 2017
  • Plague - Pipeline by Endacea Inc, H1 2017
  • Plague - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Plague - Pipeline by Grifols SA, H1 2017
  • Plague - Pipeline by iBio Inc, H1 2017
  • Plague - Pipeline by Mucosis BV, H1 2017
  • Plague - Pipeline by Paratek Pharmaceuticals Inc, H1 2017
  • Plague - Pipeline by Prokarium Ltd, H1 2017
  • Plague - Pipeline by Syntiron LLC, H1 2017
  • Plague - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
  • Plague - Pipeline by Tetraphase Pharmaceuticals Inc, H1 2017
  • Plague - Dormant Projects, H1 2017
  • Plague - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Plague, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top